Editorial Material
Biochemistry & Molecular Biology
Naoko Kanda
Summary: Psoriasis is a chronic inflammatory skin disease characterized by abnormal immune responses, hyperproliferation of keratinocytes, and comorbidities such as arthritis and cardiometabolic diseases. Recent research has uncovered potential biomarkers, therapeutic targets, and treatment options for psoriasis. Understanding the pathogenesis and treatment of psoriasis may lead to new approaches and therapies in the future.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Beatriz Burger, Roberta Nicolli Sagiorato, Isabella Cavenaghi, Hosana Gomes Rodrigues
Summary: Psoriasis is an immune-mediated skin disorder, and alterations in sphingolipids synthesis have been observed in psoriatic skin. By analyzing gene expression in psoriatic skin, several genes related to lipid metabolism, specifically sphingolipids, were found to be up-regulated in lesioned skin. These genes could potentially serve as prognostic biomarkers and therapeutic targets for psoriasis treatment.
Review
Medicine, Research & Experimental
Daciana Elena Branisteanu, Ruxandra Angela Pirvulescu, Alina Elena Spinu, Elena Andrese Porumb, Mihaela Cojocaru, Alin Codrut Nicolescu, Daniel Constantin Branisteanu, Catalina Ioana Branisteanu, Andreea Dimitriu, Anisia Iuliana Alexa, Mihaela Paula Toader
Summary: Psoriasis is a chronic inflammatory and immune-mediated condition that may affect the entire body, not just the skin. Patients with psoriasis are more likely to have comorbidities such as obesity and diabetes, and early recognition of these comorbidities is crucial for timely treatment. Dermatologists, who are often the first medical contact for psoriasis patients, play an important role in informing patients about the association between psoriasis and comorbidities, and devising prevention and treatment plans.
EXPERIMENTAL AND THERAPEUTIC MEDICINE
(2022)
Review
Dermatology
J. J. Wu, A. Kavanaugh, M. G. Lebwohl, R. Gniadecki, J. F. Merola
Summary: Psoriasis is a chronic inflammatory disorder that is often associated with comorbidities, particularly metabolic syndrome. The underlying pathophysiology of psoriasis and metabolic syndrome appears to involve genetic predispositions and inflammatory pathways. Biologic treatments for psoriasis may not only improve skin lesions but also reduce the risk of developing atherosclerosis and cardiovascular diseases.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Pharmacology & Pharmacy
Jiangluyi Cai, Lian Cui, Yu Wang, Ying Li, Xilin Zhang, Yuling Shi
Summary: Psoriasis is associated with cardiometabolic comorbidities such as cardiovascular diseases, obesity, diabetes mellitus, and metabolic syndrome, with risk increasing with psoriasis severity. Biologic therapy improves life quality of patients and reduces incidences of cardiometabolic comorbidities, but caution is needed considering the pathogenic mechanisms and prevention strategies of these comorbidities.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Dermatology
Bo Ram Mok, A-Ram Kim, Seung Hwa Baek, Ji Hae Ahn, Seung Hui Seok, Jung U. Shin, Dong Hyun Kim
Summary: This study reveals that PFN1 expression is increased in both skin and serum of patients with psoriasis, and it positively correlates with the severity of psoriasis. Both IL-17A and TNF-alpha can regulate PFN1 expression and secretion. PFN1 acts as a negative regulator of psoriatic inflammation through the suppression of I kappa B zeta, and the balanced level of PFN1 is important for I kappa B zeta regulation. Therefore, PFN1 expression can be used as a biomarker for psoriasis severity and may serve as a potential target for psoriasis treatment.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Kajetan Kielbowski, Estera Bakinowska, Piotr Ostrowski, Bartlomiej Pala, Ewa Gromowska, Klaudia Gurazda, Pawel Dec, Andrzej Modrzejewski, Andrzej Pawlik
Summary: Psoriasis is a chronic skin condition mediated by the immune system, characterized by inflammation and excessive skin cell growth. Dendritic cells, T lymphocytes, and keratinocytes play key roles in the development of psoriasis, while the IL-23/IL-17 pathway contributes to disease progression. Adipokines secreted by adipose tissue, such as adiponectin, leptin, visfatin, and resistin, have immunomodulatory effects and may influence the progression or suppression of psoriasis. Understanding the relationship between psoriasis and adipokines could lead to new diagnostic and therapeutic strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Derek Strassheim, Timothy Sullivan, David C. Irwin, Evgenia Gerasimovskaya, Tim Lahm, Dwight J. Klemm, Edward C. Dempsey, Kurt R. Stenmark, Vijaya Karoor
Summary: G protein-coupled receptors (GPCRs) were originally thought to be activated by hormones, neurotransmitters, and other mediators, but have since been found to bind endogenous metabolites with potential roles in preventing and treating metabolic and cardiovascular diseases. These receptors respond to various metabolites, including fatty acids, sugars, amino acids, and other metabolic products, many of which are dysregulated in diseases such as diabetes, dyslipidemia, and obesity.
Review
Health Care Sciences & Services
Andrea Marani, Giulio Rizzetto, Giulia Radi, Elisa Molinelli, Irene Capodaglio, Annamaria Offidani, Oriana Simonetti
Summary: Psoriasis vulgaris is a common chronic dermatosis, which is also a systemic inflammatory disease. Metabolic comorbidities such as obesity, insulin resistance, diabetes, cardiovascular disease, and dyslipidemia are commonly found in psoriatic children.
Article
Cell Biology
Min Wang, Yuqian Wang, Mengdi Zhang, Qiqi Duan, Caifeng Chen, Qiong Sun, Meng Liu, Yan Zheng, Yongping Shao
Summary: KYNU is upregulated in psoriatic skin samples and plays a crucial role in the production of inflammatory factors and the development of psoriasis-like skin inflammation. The microRNA miR-203a can inversely regulate KYNU and reduce psoriasis-related inflammatory factors. KYNU inhibitors can alleviate pathological phenotypes in IMQ-mice.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Review
Physiology
Ji Sun, Dianbao Zhang, Yiling Li
Summary: Extracellular vesicles (EVs) play a significant role in the development of metabolic associated fatty liver disease (MAFLD). They modulate communication between adipose tissue and liver through their bioactive cargos, and participate in the processes of liver inflammation and fibrosis. Therefore, EVs have the potential to be a therapeutic target and can be utilized for drug delivery in MAFLD.
FRONTIERS IN PHYSIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Arpad Szallasi
Summary: The sedentary lifestyle and unhealthy diet have led to the rise of metabolic syndrome, which is a major risk factor for type-2 diabetes and cardiovascular disease. Regular consumption of chili pepper seems to have a positive impact on health and longevity. However, the effect of dietary capsaicin on blood glucose and lipid profiles is uncertain, and the reduced mortality risk may be attributed to its beneficial effects on gut microbiota.
Review
Dermatology
Fumikazu Yamazaki
Summary: Psoriasis used to be considered a skin disease with complications related to diet and obesity, but it is now recognized as a systemic inflammatory disease with cytokines that can induce various other diseases. Individuals with psoriasis have higher incidences of cerebral and cardiovascular diseases and tend to die at a younger age. Clear guidelines have not yet been established for how much vascular lesion testing should be performed in patients with psoriasis.
JOURNAL OF DERMATOLOGY
(2021)
Review
Cell Biology
Xue Zhou, Youdong Chen, Lian Cui, Yuling Shi, Chunyuan Guo
Summary: This article reviews the crucial role of keratinocytes in the pathogenesis of psoriasis, emphasizing the significance of targeting keratinocytes for the treatment of psoriasis.
CELL DEATH & DISEASE
(2022)
Review
Immunology
Qian Shen, Rong Liu, Shiyu Tan, Xiaoding Xu, Junyue Fang, Rong Li
Summary: This article presents the pathogenesis of psoriasis and various treatment methods, with a focus on the recent advances in nanoparticles-mediated drug delivery for psoriasis treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Dermatology
Sophia Quirke-McFarlane, John Weinman, Emma S. Cook, Zenas Z. N. Yiu, Nick Dand, Sinead M. Langan, Katie Bechman, Teresa Tsakok, Kayleigh J. Mason, Helen McAteer, Freya Meynell, Bolaji Coker, Alexandra Vincent, Dominic Urmston, Amber Vesty, Jade Kelly, Camille Lancelot, Lucy Moorhead, Ines A. Barbosa, Herve Bachelez, Francesca Capon, Claudia R. Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Lluis Puig, Phyllis Spuls, Tiago Torres, Richard B. Warren, Hoseah Waweru, James B. Galloway, Christopher E. M. Griffiths, Jonathan N. Barker, Sam Norton, Catherine H. Smith, Satveer K. Mahil
Summary: This study investigated the nonadherence to immune-modifying therapy in individuals with psoriasis during the COVID-19 pandemic and its association with mental health. The most common reason for nonadherence was concerns about immunity. After adjusting for potential confounders, the association between anxiety and nonadherence to immune-modifying therapy became weaker and no longer significant. This study highlights the importance of clear and adequate communication with patients during a pandemic.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
P. Gisondi, M. Maurelli, A. Costanzo, M. Esposito, G. Girolomoni
Summary: This study aimed to investigate the safety of combining Dupilumab with other monoclonal antibodies. Through the examination of 16 cases and our clinical practice involving 8 patients, it was found that there were no adverse events related to the combination of two monoclonal antibodies, except for a few mild reactions.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Paolo Gisondi, Alice B. B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, Jose M. Lopez Pinto, Nicola Tilt, Mark Lebwohl
Summary: Patients treated with Certolizumab pegol (CZP) showed sustained improvements in quality of life over a period of 3 years, as well as positive effects on health status and work ability.
DERMATOLOGY AND THERAPY
(2023)
Letter
Dermatology
Francesco Bellinato, Paolo Gisondi, Guido Mioso, Elena Mason, Danny Straiotto, Stefano Piaserico, Giampiero Girolomoni
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Christian Ciolfi, Riccardo Balestri, Federico Bardazzi, Martina Burlando, Karin Chersi, Antonio Costanzo, Paolo Dapavo, Paolo Gisondi, Piergiorgio Malagoli, Miriam Pizzolato, Giulia Rech, Francesco Paolo Russo, Sara Battistella, Stefano Piaserico
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Marina Talamonti, Filomena Russo, Giovanna Malara, Katharina Hansel, Manuela Papini, Angelo Cattaneo, Aurora Parodi, Andrea Chiricozzi, Piergiorgio Malagoli, Federico Bardazzi, Valeria Brazzelli, Paolo Dapavo, Paolo Gisondi, Cristina Zane, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Sara Trevisini, Pina Brianti, Leonardo Pescitelli, Giovanni Gigante, Marta Bartezaghi, Luisa Caputo, Elisabetta Aloisi, Antonio Costanzo
Summary: This study compared the efficacy and safety of Secukinumab in adult patients with plaque psoriasis versus elderly patients. The results showed that the treatment was slightly less effective in elderly patients, but there were no significant differences in anxiety and depression levels between the two groups. In conclusion, Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Article
Economics
Paolo Angelo Cortesi, Carla Fornari, Paolo Gisondi, Florenzo Iannone, Ippazio Cosimo Antonazzo, Elisabetta Aloisi, Martina Fiocchi, Daniela Ritrovato, Lorenzo Giovanni Mantovani
Summary: This study assessed the budget impact of introducing secukinumab in the Italian market. The results showed that secukinumab could reduce costs, especially in patients with psoriatic arthritis. For patients with non-radiographic axial spondyloarthritis, the use of secukinumab had no significant impact on the budget.
PHARMACOECONOMICS-OPEN
(2023)
Letter
Dermatology
Rebecca Favaro, Alessandra Formai, Giulia Pavia, Luigi Gargiulo, Jessica Avagliano, Mario Valenti, Paola Facheris, Beatrice Salsano, Roberta Latorre, Francesco Bellinato, Paolo Gisondi, Alessandra Narcisi, Antonio Costanzo
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taieb, Myrto Trakatelli, Luis Puig, Alex Stratigos, EADV burden skin Dis project team
Summary: This study investigated the public perception of dermatologists in Europe and found that most people believe dermatologists play a crucial role in skin health and are satisfied with the service provided. Across different regions, people most commonly visit dermatologists for skin issues such as skin cancer screening, chronic skin diseases, and acute skin diseases.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Francesco Bellinato, Paolo Gisondi, Anna Balato, Giacomo Caldarola, Edoardo Cammarata, Elena Campione, Andrea Carugno, Andrea Conti, Monica Corazza, Paolo Dapavo, Annunziata Dattola, Vito Di Lernia, Massimo Gasperini, Salvatore Panduri, Francesca Prignano, Francesca Satolli, Enzo Spisni, Giampiero Girolomoni
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Medicine, General & Internal
Paolo Gisondi, Davide Geat, Chiara Colato, Giampiero Girolomoni
Summary: A 71-year-old woman presented with a persistent, intensely pruritic cutaneous eruption localized on the palmoplantar regions, lips and palate. The histological findings allowed to make the diagnosis of recurrent cutaneous eosinophilic vasculitis, a very rare cutaneous vasculitis characterized clinically by multiple erythematous or purpuric erythematous papules or plaques or angioedema with a relapsing course in the absence of systemic involvement and histologically by a necrotizing vasculitis of the dermal small vessels with a dominant eosinophilic infiltration. The patient was treated with oral methylprednisolone and pentoxifylline which led to a rapid resolution of the cutaneous lesions.
SAGE OPEN MEDICAL CASE REPORTS
(2023)
Letter
Dermatology
F. Bellinato, P. Gisondi, A. Dattola, A. G. Richetta, A. Costanzo, M. Valenti, C. De Simone, A. V. Marzano, M. Zussino, E. Pezzolo, M. Nacca, G. Pellacani, G. Girolomoni
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
L. Sacchelli, F. Filippi, A. Balato, R. Balestri, F. Bellinato, N. Bernardini, L. Bianchi, M. Burlando, A. Campanati, M. A. Chessa, M. Corazza, A. Di Cesare, V. Di Lernia, F. Diotallevi, M. Esposito, M. C. Fargnoli, P. Gisondi, A. Giunta, K. Hansel, M. Magnano, M. Megna, G. Odorici, F. Prignano, C. Potenza, G. Rech, M. Rovesti, A. Ruggiero, F. Satolli, L. Stingeni, D. Gibertoni, F. Bardazzi
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Correction
Dermatology
Francesco Bellinato, Paolo Gisondi, Emilio Filippucci, Francesca Tozzi, Angelo Fassio, Giovanni Adami, Luca Idolazzi
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2023)
